Cellectar BioSciences Inc. Stock
Cellectar BioSciences Inc. gained 0.670% compared to yesterday.
Based on 7 Buy predictions and 8 Sell predictions the sentiment towards Cellectar BioSciences Inc. is rather balanced.
On the other hand, the target price of 10 € is above the current price of 3.0 € for Cellectar BioSciences Inc., so the potential is actually 233.33%.
Pros and Cons of Cellectar BioSciences Inc. in the next few years
Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cellectar BioSciences Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cellectar BioSciences Inc. | 0.670% | 2.759% | -14.857% | 125.758% | 30.702% | -73.628% | - |
| Beximco Pharmaceuticals Ltd. GDR | - | 0.000% | -1.408% | 2.439% | -4.545% | -55.789% | -26.316% |
| Arca Biopharma | -1.270% | -8.589% | 4.196% | 58.511% | 91.640% | 12.030% | -94.744% |
| SELLAS Life Sciences Group Inc | 1.010% | 2.591% | -10.811% | -27.027% | 21.846% | -82.027% | -99.677% |
Comments
Cellectar Biosciences, Inc. (NASDAQ: CLRB) was upgraded by analysts at StockNews.com to a "sell" rating.
Show more
Ratings data for CLRB provided by MarketBeat
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its price target raised by analysts at Roth Mkm from $20.00 to $28.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CLRB provided by MarketBeat
Cellectar Biosciences, Inc. (NASDAQ: CLRB) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $12.00 price target on the stock, up previously from $11.00.
Show more
Ratings data for CLRB provided by MarketBeat